ReviewMolecular biotechnology2003
Clinical implication of p53 mutation in lung cancer.
Review in Molecular biotechnology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024Review
- Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma.Cancer science · 2024Article
- Molecular mechanism of radiation tolerance in lung adenocarcinoma cells using single-cell RNA sequencing.Journal of cellular and molecular medicine · 2024Article
- Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.Cancer medicine · 2024Article
- Article
- Incidental discovery of acute myeloid leukemia during liquid biopsy of a lung cancer patient.Cold Spring Harbor molecular case studies · 2022Article
- Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?Cancer biology & therapy · 2020Review
- The Phenoxyphenol Compound 4-HPPP Selectively Induces Antiproliferation Effects and Apoptosis in Human Lung Cancer Cells through Aneupolyploidization and ATR DNA Repair Signaling.Oxidative medicine and cellular longevity · 2020Article
- Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.Journal of oncology · 2019Article
- Wild-type and mutant p53 differentially modulate miR-124/iASPP feedback following pohotodynamic therapy in human colon cancer cell line.Cell death & disease · 2017Article
- Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer.Oncology letters · 2016Article
- PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.International journal of cancer · 2014Article
- The association between smoking and ectopic pregnancy: why nicotine is BAD for your fallopian tube.PloS one · 2014Article
- [P53 family proteins provide new insights into lung carcinogenesis and clinical treatment].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2013Review
- Genotyping of Human Papillomavirus and TP53 Mutaions at Exons 5 to 7 in Lung Cancer Patients from Iran.BioImpacts : BI · 2013Article
- Allele specific gain-of-function activity of p53 mutants in lung cancer cells.Biochemical and biophysical research communications · 2012Article
- The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion.Investigational new drugs · 2012Article
- Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.Genes & cancer · 2012Article
- The Role of p53 in Marijuana Smoke Condensates-induced Genotoxicity and Apoptosis.Environmental health and toxicology · 2012Article
- Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival.Cancer science · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer development involves multiple genetic abnormalities leading to malignant transformation of the bronchial epithelial cells, followed by invasion and metastasis. One of the most common changes is mutation of the p53 tumor suppressor gene. The frequency of p53 alterations in lung cancer is highest in small cell and squamous cell carcinomas. A genetic "signature" of the type of p53 mutations has been associated with carcinogens in cigarette smoke. The majority of clinical studies suggest that lung cancers with p53 alterations carry a worse prognosis, and may be relatively more resistant to chemotherapy and radiation. An understanding of the role of p53 in human lung cancer may lead to more rational targeted approaches for treating this disease. P53 gene replacement is currently under clinical investigation but clearly more effective means of gene deliver to the tumor cells are required. Novel approaches to lung cancer therapy are needed to improve the observed poor patient survival despite current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.